Showing results (271-280 of 333) with videos related to

Sort By:
Pageof 34
JTO Clinical and Research Reports|June 3, 2025
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese SubsetMakoto Nishio, Takashi Seto, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|February 2, 2023
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapyMasayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, et al.
Cancer Science|September 9, 2025
Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLCSatoru Kitazono, Akira Ono, Tetsuji Kawamura, et al.
JTO Clinical and Research Reports|October 14, 2024
Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L StudyHirotsugu Kenmotsu, Kazuko Sakai, Keita Mori, et al.
Cancer Medicine|May 2, 2013
Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cellsDaisuke Tamura, Tokuzo Arao, Tomoyuki Nagai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, et al.
Journal for Immunotherapy of Cancer|February 2, 2022
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, et al.
Cancer Research Communications|October 11, 2024
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung CancerHidetoshi Hayashi, Makoto Nishio, Hiroaki Akamatsu, et al.
JTO Clinical and Research Reports|April 10, 2023
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)Satoru Miura, Makoto Nishio, Hiroaki Akamatsu, et al.
Lung Cancer (Amsterdam, Netherlands)|April 21, 2026
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational studyTakashi Kurosaki, Shinichiro Suzuki, Yasutaka Watanabe, et al.
Pageof 34